Dendreon Corp fka DNDNQ

[steveporsche]

Questions for the Board relating to 9902B hitting requiried results. What factors led to the relatively poor results of 9902A? How much of the shortfall in log rank p-value and HR is attributable to smaller size? trial imbalances favoring placebo, etc? Why should the results of 9902B look much more like 9901 than 9902A at the interim and final? If 9902B mirrors the combined 9901/9902A results, what might the results of 9902B using the SPA prespecified cox analysis look like at the interim and final? Do you feel that the combined 9901/9902A results could serve as a proxy for 9902B? How much of a margin of error is involved? Could the results of a few patients sway the results one way or the other if we roughly mirrored the combined 9901 and 9902A results? How might the relatively sicker patient population effect the results? How might slow ramp up on enrollment of 9902B affect the results at the interim and final for an event given trial? How do long-term survivors factor into the results of an event driven trial? Just trying to get a handle on some of these questions, as we have plenty of time to discuss. Thanks for your thoughts.